On October 28, 2026, Enlivex Ltd. announced that it has made notable advancements in its Phase 2b clinical trial of Allocetra™, a treatment for moderate-to-severe age-related symptomatic primary knee osteoarthritis. This development is significant for the company as it seeks to establish itself as a leader in the treatment of this common ailment. With 135 patients randomized and administered the first injection of Allocetra™, the trial is actively recruiting participants across the United States and Europe.

Enlivex Ltd. operates within the finance services sector, as classified under SIC 6199. The company is listed on the Nasdaq under the ticker symbol ENLV and is recognized as a non-accelerated filer. The recent filing, dated October 28, 2026, marks an important update in the company’s ongoing clinical efforts.

The filing states, "135 patients, out of a total planned 182, have been randomized and were administered the first injection of Allocetra™; enrollment actively ongoing at clinical sites in the United States and in Europe." The company expects to report topline six-month data by mid-2027, which will be crucial in assessing the efficacy of the treatment.

This announcement may affect various stakeholders, including patients suffering from knee osteoarthritis, healthcare providers, and investors in the biotech and finance services sectors. The successful outcome of this trial could lead to new treatment options for millions of individuals affected by this debilitating condition.

The filing does not specify what happens next, but the company is expected to continue its recruitment efforts and monitor the trial's progress closely.